Climb Bio, Inc. (CLYM) - Q1 2026 Filing Summary
Business Context and Reporting Period
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases. The company focuses on two primary product candidates: budoprutug (an anti-CD19 monoclonal antibody) and CLYM116 (an anti-APRIL monoclonal antibody). This summary covers the quarterly period ended March 31, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(13.7) million | $(20.8) million |
| Net Loss Per Share | $(0.20) | $(0.31) |
| Operating Expenses | $15.2 million | $23.0 million |
| Cash, Cash Equivalents & Marketable Securities | $146.3 million | $160.3 million (Dec 31, 2025) |
| Accumulated Deficit | $(303.4) million | $(250.7) million (Dec 31, 2025) |
| Net Cash Used in Operating Activities | $(14.4) million | $(15.4) million |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $7.1 million compared to Q1 2025, primarily driven by a significant reduction in Research and Development (R&D) expenses.
- R&D Expense Decline: R&D expenses dropped from $17.3 million in Q1 2025 to $9.4 million in Q1 2026. This decrease is largely attributable to the absence of the $9.0 million upfront payment made in Q1 2025 for the CLYM116 license agreement with Mabworks.
- Investing Activities: Net cash used in investing activities decreased significantly to $13.0 million (from $42.8 million in Q1 2025) due to a lower net purchase of marketable securities.
- Interest Income: Interest income declined to $1.5 million from $2.3 million, reflecting lower invested balances during the period.
Guidance, Outlook, and Risks
- Cash Runway: As of March 31, 2026, the company held $146.3 million in cash and marketable securities. Management expects this balance to fund operations into 2028, excluding proceeds from a subsequent private placement.
- Recent Financing: In April 2026 (subsequent to the reporting period), the company completed a private placement raising approximately $110.0 million. Management is evaluating the impact of this financing on its operating plan and will provide updated guidance later.
- Clinical Progress:
- Budoprutug: Phase 2 trial in primary membranous nephropathy (pMN) is actively enrolling; initial data expected in Q4 2026. Phase 1b/2a trial in immune thrombocytopenia (ITP) is ongoing with initial data expected in June 2026. Phase 1b trial in systemic lupus erythematosus (SLE) is enrolling.
- CLYM116: Phase 1 trial in healthy volunteers initiated in November 2025; initial PK/PD data expected mid-2026.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of March 31, 2026, due to two unremediated material weaknesses in internal control over financial reporting (specifically regarding the control environment and formal accounting policies).
- Legal Proceedings: A dispute regarding potential milestone payments under the Asset Purchase Agreement with Acelyrin/Alumis is pending in Delaware Superior Court.
Investor Verification Checklist
- Verify the status and timeline for remediation of the identified material weaknesses in internal controls over financial reporting.
- Confirm the final net proceeds and dilution impact of the April 2026 private placement ($110 million gross).
- Monitor the outcome of the pending litigation with Alumis Inc. regarding milestone payments for budoprutug.
- Track patient enrollment rates and safety data for the budoprutug Phase 2 pMN trial and Phase 1b/2a ITP trial.
- Assess the impact of the BIOSECURE Act and potential tariffs on the company's reliance on Chinese suppliers and partners (e.g., Mabworks, WuXi).